Log In
Print
BCIQ
Print
Print this Print this
 

ACC-001, PF-05236806, PF-5236806

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionBeta amyloid-related immunotherapeutic conjugate
Molecular Target Beta amyloid
Mechanism of ActionVaccine
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today